Jennifer is currently accepting new patients and
generally has the soonest appointment availability.
For most new patients, we recommend scheduling with
Jennifer as the first choice.
Dr. Gabriella Farkas, MD, PhD
Limited Availability
Psychiatrist · MD, PhD
Dr. Farkas continues to see new patients on a more
limited basis. Patients specifically seeking an
appointment with Dr. Farkas may view her availability
in the scheduling portal.
On the scheduling screen, Jennifer Reilly will appear
first. Select your preferred clinician to continue
with available appointment times.
Published June 15, 2026 · 3 min read · Last reviewed 2026-06-25
Anxiety disorders are the most common psychiatric conditions in the United States, affecting nearly one in five adults annually according to the NIMH — Anxiety Disorders. Yet the difference between treated and untreated anxiety — and between adequately treated and partially treated — is enormous in day-to-day functioning. This article addresses panic attack vs anxiety attack with the level of specificity patients deserve when making informed decisions about care.
Key Takeaways
Panic Attacks vs. Anxiety Attacks responds well to evidence-based treatment when the diagnosis is precise — anxiety subtypes (GAD, panic, social, health anxiety, OCD) need different approaches.
First-line care typically includes an SSRI or SNRI plus structured therapy; benzodiazepines are reserved for narrow indications.
Non-addictive options exist for nearly every anxiety presentation — including buspirone, hydroxyzine, beta-blockers in select cases, and antihistamine-class agents.
Untreated anxiety carries cardiovascular, metabolic, and quality-of-life costs that often outweigh the perceived risks of treatment.
Evidence-based psychiatric care for panic attack vs anxiety attack.
What Panic Attacks vs. Anxiety Attacks Looks Like Clinically
Anxiety disorders are not a single condition. NIMH — Anxiety Disorders distinguishes generalized anxiety disorder, panic disorder, social anxiety disorder, specific phobias, agoraphobia, and separation anxiety — each with different treatment evidence. Anxiety and Depression Association of America provides additional patient-facing detail.
The distinction matters because evidence-based treatment varies meaningfully: panic disorder responds particularly well to SSRIs plus CBT; social anxiety has its own evidence base; health anxiety (illness anxiety disorder) requires specific framing. Treating all anxiety identically misses opportunities to match patients to the most effective approach.
First-Line Treatment — What the Evidence Supports
For most anxiety disorders, the evidence base supports an SSRI or SNRI plus a structured psychotherapy approach — most commonly CBT. APA Practice Guidelines practice guidelines and the broader literature catalogued in PubMed (NLM) converge on this framework.
SNRIs — venlafaxine XR, duloxetine — particularly useful when comorbid depressive or somatic symptoms are prominent.
Buspirone — non-addictive, useful for generalized anxiety, works without sedation or cognitive impairment.
Hydroxyzine — H1 antihistamine with anxiolytic properties, non-controlled, useful for situational anxiety.
Beta-blockers — propranolol for performance anxiety with physical symptoms (tremor, tachycardia).
Benzodiazepines have a narrow legitimate role — short-term, specific indications — but are not first-line for chronic anxiety per current practice standards.
Non-Addictive Anxiety Treatment
One of the most useful clinical commitments in anxiety care is prioritizing non-addictive options. The evidence base supports several:
SSRIs and SNRIs — first-line, no dependence potential.
Buspirone — anxiolytic without sedation, dependency, or cognitive dulling.
Hydroxyzine — useful for situational anxiety, sleep-onset anxiety.
Beta-blockers — propranolol for the physical symptoms of performance anxiety.
Gabapentin — selected anxiety contexts, particularly with comorbid pain or sleep issues, used judiciously.
For patients dealing with panic attack vs anxiety attack, the goal is durable improvement, not chronic dependence on a controlled substance.
When Specialist Care Helps Most
Most anxiety responds to first-line care in primary care or outpatient psychiatry. Specialist evaluation becomes valuable when:
Multiple first-line trials have not produced adequate response
Anxiety is complicated by significant depression, trauma, or substance use
Benzodiazepine use has accumulated without a clear taper plan
Health anxiety is dominating clinical care to the exclusion of other needs
Anxiety presents in the perinatal period, perimenopause, or geriatric context — settings where prescribing requires extra precision
Cognitive behavioral therapy, particularly with exposure components for relevant subtypes, has among the strongest evidence bases in mental health. Combined with appropriate medication, outcomes typically exceed either modality alone for moderate-to-severe anxiety.
Psychiatry coordinates with therapy — the goal is medication that reduces symptoms enough to engage productively with exposure work, while therapy builds the durable skills that protect against relapse. Patients dealing with panic attack vs anxiety attack benefit when both ends are addressed deliberately.
Common Questions About Panic Attacks vs. Anxiety Attacks
Are SSRIs safe for long-term use?
For most patients, yes — decades of post-market data per PubMed (NLM) support long-term safety. Specific monitoring (bleeding risk, sexual side effects, weight, mood) is part of routine care.
Why not just use benzodiazepines if they work fast?
Benzodiazepines work fast but produce tolerance, dependency, and cognitive impairment with chronic use. Per current practice guidelines, they’re appropriate for narrow short-term indications — not chronic anxiety management.
Will I have to take medication forever?
Not necessarily. Many patients taper successfully after a period of remission combined with skill-building from therapy. The decision is individualized.
⚠️
The Problem
Incomplete or delayed care
Many patients with panic attack vs anxiety attack receive treatment that is not fully optimized — subtherapeutic dosing, premature switching, or missing comorbidity recognition.
🔬
The Approach
MD/PhD-level evaluation
Diagnostic precision, evidence-based prescribing, measurement-based follow-up, and willingness to deprescribe.
✓
The Outcome
Durable improvement
Treatment that achieves and maintains remission — not just partial response that erodes quality of life.
Specialist evaluation for panic attack vs anxiety attack?
MD/PhD-trained psychiatric care via telehealth across South Carolina, New York, and Virginia.
Educational content only. This article does not constitute medical advice and does not establish a doctor-patient relationship. If you are experiencing a psychiatric emergency, call 911 or 988, or go to your nearest emergency room. Treatment decisions should be made in collaboration with a qualified clinician familiar with your specific circumstances.
Take the Next Step
MD/PhD-level psychiatric care. Most new patients seen within 2–4 weeks. Telehealth across South Carolina, New York, and Virginia. In-network with Aetna and Cigna.